Ahmed Koriesh/LinkedIn

Oct 26, 2025, 16:35

Ahmed Koriesh on Thrombolysis in Stroke Patients on DOACs

Ahmed Koriesh, Director Hospital Neurology Service at Cleveland Clinic Florida, shared on LinkedIn:

”Thrombolysis in Stroke Patients on DOACs — Time to Rethink the Contraindication?

For years, recent DOAC use meant no tPA — a red line in stroke protocols.

Now, a new study challenges this rule.

DO-IT Target Analysis (2025)
28 stroke centers, 1,342 DOAC patients
Objective: Compare outcomes of IVT vs no IVT, and reversal vs no reversal.

Results:

Interpretation: IV thrombolysis in recent DOAC users appears safe, effective, and not dependent on reversal.

DOAC-IVT (2023)
64 centers • >33,000 patients
Objective: Assess bleeding risk with IVT after recent DOAC intake (< 48 h).

Results:

Interpretation: Carefully selected patients on DOACs may safely receive IVT — even without waiting 48 hours.

Clinical Pearl: We’re shifting from “automatic exclusion” to “measured inclusion.”

Bottom Line: Evidence is growing that DOAC use ≠ absolute contraindication for thrombolysis.

Awaiting further prospective trials (PEARL-DOAC, Prospective DOAC-IVT).

Stroke codes are evolving — from “On DOAC = no tPA” to ”When was the last dose?”’

Ahmed Koriesh on Thrombolysis in Stroke Patients on DOACs

Stay updated with Hemostasis Today.

Ahmed Koriesh DO IT DOAC-IVT DOACs Health Hematology Hemostasis Hemostasis Today IVT Medicine PEARL-DOAC stroke Thrombolysis thrombosis tPA

'

'

'

'

'

Hemostasis Today